Ticker brief · 2026-10-18

MIRM MIRUM PHARMACEUTICALS INC

Positive EXPAND data meets concentrated buying and unresolved regulatory skepticism

Consumer, Non-cyclical · Pharmaceuticals

Lean: bullish
last close
$80.39
1 day
-3.3%
14 days
-6.5%
mkt cap
$7.7B
signals 14d
52
authors 14d
12
crowd 14d
+0.8σ

MIRM leans bullish, with HIGH-credibility confirmation of positive Phase 3 data but discretionary buying concentrated in one MEDIUM-HIGH author. The decisive late-week shift was Biotech2k1 reversing earlier exit plans and buying three times toward a minimum 3% allocation near 82, 81 and below 80. The disclosed trade is price-disciplined cash-equity accumulation; valuation limits and a separate phase-2-based filing objection remain unresolved.

BULL CAMP3 claims

Positive Phase 3 EXPAND results and plans for an expanded-indication filing support the clinical bull case. Biotech2k1 supplies the accumulation thesis, adding as the price approaches $80.

Key voices
@BiotechCHHIGHB+1.42@Biotech2k1MEDIUM-HIGHA+1.11@OzmosiHealthMEDIUMC
“Positive Phase 3 data accompanies plans to file for an expanded indication.”— @BiotechCH ·
BEAR / SKEPTIC3 claims

Biotech2k1 argues peak-sales estimates limit valuation upside and positive Livmarli data only offsets earlier setbacks. A separate objection anticipates FDA refusal of a phase-2-based filing after a request for phase 3 data.

Key voices
@Biotech2k1MEDIUM-HIGHA+1.11
“Expects FDA refusal of a phase-2-based filing after an FDA request for phase 3 data.”— @Biotech2k1 ·
Hypotheses7direction · basis · magnitude · supporters — NEW = first seen this week
▲Mirum's positive Phase 3 EXPAND primary-endpoint result is a favorable clinical catalyst supporting confidence in the company's development program.
bullcatalystmedium if true~5d horizonNEW-6.6% since 2026-10-12
@Biotech2k1MEDIUM-HIGHA+1.111s · insight@OzmosiHealthMEDIUMC1s@ElliottWaveSageLOW-MEDIUMC+0.281s@BiotechCHHIGHB+1.421s · insight
▲Mirum's planned U.S. expanded-indication filing creates a distinct regulatory opportunity following the positive Phase 3 clinical readout.
bullcatalystmedium if true~10d horizonNEWthin⚠ single-author-6.6% since 2026-10-12
@ElliottWaveSageLOW-MEDIUMC+0.281s@BiotechCHHIGHB+1.421s · insight
▲MIRM weakness toward $80 offers an attractive accumulation opportunity, with price-disciplined purchases supporting a larger portfolio allocation.
bullfundamentalmedium if true~30d horizonNEW⚠ single-author+1.0% since 2026-10-13
@Biotech2k1MEDIUM-HIGHA+1.116s · insight
▼MIRM's valuation is excessive relative to estimated peak sales, limiting prospective upside and making alternative biotech pipelines more attractive.
bearfundamentalmedium if true~30d horizonNEWthin⚠ single-author-6.6% since 2026-10-12
@Biotech2k1MEDIUM-HIGHA+1.112s · insight
▼Positive Livmarli data merely offsets earlier program setbacks, leaving MIRM's valuation unchanged rather than justifying a fresh upward re-rating.
bearfundamentalmedium if true~20d horizonNEWthin⚠ single-author-6.6% since 2026-10-12
@Biotech2k1MEDIUM-HIGHA+1.111s · insight
▼Mirum's proposed phase-2-based filing risks FDA refusal because the agency requested phase 3 data, threatening the anticipated regulatory pathway.
bearfundamentallarge if true~40d horizonNEWthin⚠ single-author+1.0% since 2026-10-13
@Biotech2k1MEDIUM-HIGHA+1.111s · insight
◆MIRM rally strength offers an opportunity to execute standing exits and recycle portfolio capital, without requiring an outright downside bet.
neutralpositioningsmall if true~10d horizon⚠ single-author-6.5% since 2026-10-09
@Biotech2k1MEDIUM-HIGHA+1.114s · insight
Direct calls4authors taking explicit directional positions
@Biotech2k1MEDIUM-HIGHA+1.11
Made three same-day MIRM purchases near 82, 81 and below 80 to reach a minimum 3% allocation.
@Biotech2k1MEDIUM-HIGHA+1.11
Added MIRM alongside other biotech positions on October 16.
@Biotech2k1MEDIUM-HIGHA+1.11
Earlier planned to sell MIRM because estimated peak sales limited upside relative to alternative pipelines.
@Biotech2k1MEDIUM-HIGHA+1.11
Earlier maintained a GTC sale order while describing valuation as excessive relative to peak sales.
News / data points4discrete events + data quoted by authors
@BiotechCHHIGHB+1.42
Positive Phase 3 data accompanies plans to file for an expanded indication.
2026-10-16+0.3% since
@OzmosiHealthMEDIUMC
Mirum's Phase 3 EXPAND study met its primary endpoint.
2026-10-12-6.6% since
@ElliottWaveSageLOW-MEDIUMC+0.28
The Phase 3 primary-endpoint result supports a planned U.S. label filing.
2026-10-12-6.6% since
@AlertsAndNewsLOW-MEDIUMC-3.92
Scheduled topline Phase 3 EXPAND results for October 12 at 8:30 a.m. ET.
2026-10-11-6.5% since
Position disclosures3skin in the game
@Biotech2k1MEDIUM-HIGHA+1.11
By October 16, reported three same-day MIRM purchases near 82, 81 and below 80 toward a minimum 3% allocation.
@Biotech2k1MEDIUM-HIGHA+1.11
On October 14, disclosed adding to an existing MIRM position.
@Biotech2k1MEDIUM-HIGHA+1.11
On October 13, reported adding MIRM and seeking a larger position as price approached $80.
Desk readconvergence assessment
Independent reporting converges on positive Phase 3 EXPAND results; valuation, accumulation and regulatory skepticism depend primarily on Biotech2k1, whose 23 signals dominate activity and whose trader_score_20 is -0.97. Bulls have independent HIGH-credibility corroboration, while the bear camp has no independent corroborating author; repeated purchases represent one buyer, not broad investor consensus. Clarification of which filing faces the phase-2-based objection and updated peak-sales economics would change conviction; all supplied prior hypotheses are unscored and provide no realized-performance validation.
Options inteloptions-surface reads · latest available day per source
metricreadingcontext
IV — ATM 30d97%IV/HV 2.03× (as of 2026-05-01)
Skew — 25Δ RR 30d+0.02125Δ call IV − put IV
Net dealer OI (NDOI)+0.24 elevated5-session Δ +0.14 (as of 2026-05-01)
OI alarmquietlast alarm 2026-05-01 (z=2.2)
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.65 (−1 bearish … +1 bullish)
Who spoke12
authorgradetrader scoresignalsmean sent
@Biotech2k1A+1.1135+0.36
@BiopharmIQB·5+0.08
@OzmosiHealthC·3+0.23
@AlertsAndNewsC-3.921+0.00
@BriefingcomB-2.261+0.30
@tenet_researchC-1.231+0.00
@BrandonVanZeeC-1.041+0.00
@TENETTRADEGROUPC-0.651+0.00
@PrismMarketViewC·1+0.50
@semodoughC-1.061+0.05
@ElliottWaveSageC+0.281+0.50
@BiotechCHB+1.421+0.60
Recent signals30of 52 in 14d — receipts included
date (PT)authorsentwhat they saidsince thenreceipt
2026-10-16@BiotechCH+0.60MIRM announced positive Phase 3 data and plans to file for an expanded indication.+0.3%
2026-10-16@Biotech2k1+0.75Built MIRM toward a 3% position with purchases near 82, 81 and below 80. — The author reports three same-day MIRM purchases to reach a minimum 3% allocation.+0.3%
2026-10-16@Biotech2k1+0.70Added MIRM, COGT, SMMT and IMNM this morning. — The author explicitly reports adding four biotech positions.+0.3%
2026-10-16@Biotech2k1+0.55The author identifies high-quality biotech names trading at substantial discounts from their highs.+0.3%
2026-10-16@Biotech2k1+0.65The author presents a researched ranking of core biotech holdings, led by INSM.+0.3%
2026-10-15@Biotech2k1+0.70Identifies a basket of biotech names viewed as mispriced excellence.-2.4%
2026-10-14@Biotech2k1+0.55Discloses additions to existing MIRM and COGT positions.+0.5%
2026-10-14@Biotech2k1+0.45Calls ARWR high quality and attractively valued while discussing alternative biotech selections.+0.5%
2026-10-13@Biotech2k1+0.70Names a ranked basket of top biotech ideas based on strong fundamentals.+1.0%
2026-10-13@Biotech2k1+0.65Calls AXSM and CYTK cheap while disclosing preference for MDGL and MIRM.+1.0%
2026-10-13@Biotech2k1+0.70Reports buying more MIRM while emphasizing price discipline.+1.0%
2026-10-13@Biotech2k1+0.75Reports adding MIRM and wanting a larger position as price approaches $80.+1.0%
2026-10-13@OzmosiHealth+0.00Reports presentation of Phase 3 maralixibat biliary-atresia results.+1.0%
2026-10-13@Biotech2k1+0.75Discloses 45% biotech weight, a 50% threshold and six core or potential holdings.+1.0%
2026-10-13@Biotech2k1-0.75Expects FDA refusal because Mirum plans a phase-2-based filing despite an FDA request for phase 3 data.+1.0%
2026-10-12@Biotech2k1+0.10Discloses biotech buying, 44.35% weighting and preferred value names.-6.6%
2026-10-12@BiopharmIQ+0.10Summarizes same-day biotech price reactions to clinical catalysts.-6.6%
2026-10-12@BiopharmIQ+0.10Catalogs opening price moves tied to biotech data releases.-6.6%
2026-10-12@ElliottWaveSage+0.50Phase 3 study met its primary endpoint and supports a planned U.S. label filing.-6.6%
2026-10-12@OzmosiHealth+0.60Mirum's Phase 3 EXPAND study met its primary endpoint.-6.6%
2026-10-12@semodough+0.05Lists expected timing for multiple Phase 3 clinical catalysts and filings.-6.6%
2026-10-12@Biotech2k1+0.10Reports deciding not to sell MIRM and instead buying MDGL.-6.6%
2026-10-12@PrismMarketView+0.50Summarizes a Phase 3 miss, FDA-path efforts, an approval and another developer's oral program.-6.6%
2026-10-12@Biotech2k1-0.15Says positive Livmarli data merely offsets prior program setbacks, leaving valuation unchanged.-6.6%
2026-10-12@TENETTRADEGROUP+0.00Premarket-movers list provides names but no visible direction or magnitude in the text.-6.6%
2026-10-12@BrandonVanZee+0.00Names three stocks in a morning-market segment without visible direction or analysis.-6.6%
2026-10-12@tenet_research+0.00Lists premarket movers without performance figures or directional details.-6.6%
2026-10-12@Biotech2k1-0.65A standing GTC sell order will exit MIRM. — Calls the valuation excessive relative to peak sales and says a GTC sale order is waiting.-6.6%
2026-10-12@Biotech2k1+0.50Reports Mirum's Phase 3 EXPAND study met its primary endpoint.-6.6%
2026-10-12@Briefingcom+0.30Lists the largest premarket gaps, led by TRAX and CCC higher and PXED lower.-6.6%

“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.